178 related articles for article (PubMed ID: 24281006)
1. Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms.
Gujar SA; Clements D; Dielschneider R; Helson E; Marcato P; Lee PW
Br J Cancer; 2014 Jan; 110(1):83-93. PubMed ID: 24281006
[TBL] [Abstract][Full Text] [Related]
2. Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis.
Gebremeskel S; Nelson A; Walker B; Oliphant T; Lobert L; Mahoney D; Johnston B
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722907
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity.
Ilett EJ; Prestwich RJ; Kottke T; Errington F; Thompson JM; Harrington KJ; Pandha HS; Coffey M; Selby PJ; Vile RG; Melcher AA
Gene Ther; 2009 May; 16(5):689-99. PubMed ID: 19282847
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer.
Raki M; Särkioja M; Desmond RA; Chen DT; Bützow R; Hemminki A; Kanerva A
Gynecol Oncol; 2008 Jan; 108(1):166-72. PubMed ID: 17950450
[TBL] [Abstract][Full Text] [Related]
5. Multifaceted therapeutic targeting of ovarian peritoneal carcinomatosis through virus-induced immunomodulation.
Gujar S; Dielschneider R; Clements D; Helson E; Shmulevitz M; Marcato P; Pan D; Pan LZ; Ahn DG; Alawadhi A; Lee PW
Mol Ther; 2013 Feb; 21(2):338-47. PubMed ID: 23299799
[TBL] [Abstract][Full Text] [Related]
6. Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites.
Jennings VA; Ilett EJ; Scott KJ; West EJ; Vile R; Pandha H; Harrington K; Young A; Hall GD; Coffey M; Selby P; Errington-Mais F; Melcher AA
Int J Cancer; 2014 Mar; 134(5):1091-101. PubMed ID: 23982804
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic viral therapy using reovirus.
Thirukkumaran C; Morris DG
Methods Mol Biol; 2009; 542():607-34. PubMed ID: 19565924
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma.
Errington F; White CL; Twigger KR; Rose A; Scott K; Steele L; Ilett LJ; Prestwich R; Pandha HS; Coffey M; Selby P; Vile R; Harrington KJ; Melcher AA
Gene Ther; 2008 Sep; 15(18):1257-70. PubMed ID: 18401435
[TBL] [Abstract][Full Text] [Related]
9. Advances in oncolytic adenovirus therapy for pancreatic cancer.
Nattress CB; Halldén G
Cancer Lett; 2018 Oct; 434():56-69. PubMed ID: 29981812
[TBL] [Abstract][Full Text] [Related]
10. Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus.
Qiao J; Wang H; Kottke T; White C; Twigger K; Diaz RM; Thompson J; Selby P; de Bono J; Melcher A; Pandha H; Coffey M; Vile R; Harrington K
Clin Cancer Res; 2008 Jan; 14(1):259-69. PubMed ID: 18172278
[TBL] [Abstract][Full Text] [Related]
11. Enhanced Killing of Triple-Negative Breast Cancer Cells by Reassortant Reovirus and Topoisomerase Inhibitors.
Rodríguez Stewart RM; Berry JTL; Berger AK; Yoon SB; Hirsch AL; Guberman JA; Patel NB; Tharp GK; Bosinger SE; Mainou BA
J Virol; 2019 Dec; 93(23):. PubMed ID: 31511390
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer.
Lolkema MP; Arkenau HT; Harrington K; Roxburgh P; Morrison R; Roulstone V; Twigger K; Coffey M; Mettinger K; Gill G; Evans TR; de Bono JS
Clin Cancer Res; 2011 Feb; 17(3):581-8. PubMed ID: 21106728
[TBL] [Abstract][Full Text] [Related]
13. Role of Myeloid Cells in Oncolytic Reovirus-Based Cancer Therapy.
Kumar V; Giacomantonio MA; Gujar S
Viruses; 2021 Apr; 13(4):. PubMed ID: 33920168
[TBL] [Abstract][Full Text] [Related]
14. Repurposing Sunitinib with Oncolytic Reovirus as a Novel Immunotherapeutic Strategy for Renal Cell Carcinoma.
Lawson KA; Mostafa AA; Shi ZQ; Spurrell J; Chen W; Kawakami J; Gratton K; Thakur S; Morris DG
Clin Cancer Res; 2016 Dec; 22(23):5839-5850. PubMed ID: 27220962
[TBL] [Abstract][Full Text] [Related]
15. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity.
Vincent J; Mignot G; Chalmin F; Ladoire S; Bruchard M; Chevriaux A; Martin F; Apetoh L; Rébé C; Ghiringhelli F
Cancer Res; 2010 Apr; 70(8):3052-61. PubMed ID: 20388795
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic Viral Therapy Using Reovirus.
Thirukkumaran C; Morris DG
Methods Mol Biol; 2015; 1317():187-223. PubMed ID: 26072409
[TBL] [Abstract][Full Text] [Related]
17. Reovirus virotherapy overrides tumor antigen presentation evasion and promotes protective antitumor immunity.
Gujar SA; Marcato P; Pan D; Lee PW
Mol Cancer Ther; 2010 Nov; 9(11):2924-33. PubMed ID: 20978162
[TBL] [Abstract][Full Text] [Related]
18. Single Amino Acid Differences between Closely Related Reovirus T3D Lab Strains Alter Oncolytic Potency
Mohamed A; Clements DR; Gujar SA; Lee PW; Smiley JR; Shmulevitz M
J Virol; 2020 Jan; 94(4):. PubMed ID: 31748391
[TBL] [Abstract][Full Text] [Related]
19. Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.
Heinemann L; Simpson GR; Boxall A; Kottke T; Relph KL; Vile R; Melcher A; Prestwich R; Harrington KJ; Morgan R; Pandha HS
BMC Cancer; 2011 Jun; 11():221. PubMed ID: 21645351
[TBL] [Abstract][Full Text] [Related]
20. PUMA and NF-kB Are Cell Signaling Predictors of Reovirus Oncolysis of Breast Cancer.
Thirukkumaran C; Shi ZQ; Thirukkumaran P; Luider J; Kopciuk K; Spurrell J; Elzinga K; Morris D
PLoS One; 2017; 12(1):e0168233. PubMed ID: 28099441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
